Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Nabriva Therapeutics stock
Learn how to easily invest in Nabriva Therapeutics stock.
Nabriva Therapeutics plc is a biotechnology business based in the US. Nabriva Therapeutics shares (NBRV) are listed on the NASDAQ and all prices are listed in US Dollars. Nabriva Therapeutics employs 72 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Nabriva Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – NBRV – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Nabriva Therapeutics stock price (NASDAQ: NBRV)Use our graph to track the performance of NBRV stocks over time.
Nabriva Therapeutics shares at a glance
|Latest market close||$0.45|
|52-week range||$0.52 - $3.49|
|50-day moving average||$0.78|
|200-day moving average||$1.15|
|Wall St. target price||$2.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.62|
Buy Nabriva Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Nabriva Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Nabriva Therapeutics price performance over time
|1 week (2022-01-18)||-11.51%|
|1 month (2021-12-23)||-26.16%|
|3 months (2021-10-25)||-59.79%|
|6 months (2021-07-23)||-60.14%|
|1 year (2021-01-25)||-85.47%|
|2 years (2020-01-24)||-66.64%|
|3 years (2019-01-25)||1.92|
|5 years (2017-01-25)||8.21|
Nabriva Therapeutics financials
|Revenue TTM||$22.1 million|
|Gross profit TTM||$-10,841,000|
|Return on assets TTM||-46.19%|
|Return on equity TTM||-108.96%|
|Market capitalisation||$30.3 million|
TTM: trailing 12 months
Nabriva Therapeutics share dividends
We're not expecting Nabriva Therapeutics to pay a dividend over the next 12 months.
Have Nabriva Therapeutics's shares ever split?
Nabriva Therapeutics's shares were split on a 1:10 basis on 2 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nabriva Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Nabriva Therapeutics shares which in turn could have impacted Nabriva Therapeutics's share price.
Nabriva Therapeutics share price volatility
Over the last 12 months, Nabriva Therapeutics's shares have ranged in value from as little as $0.519 up to $3.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nabriva Therapeutics's is 1.6163. This would suggest that Nabriva Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Nabriva Therapeutics overview
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI). It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. .
Nabriva Therapeutics in the news
What to watch today: Wall Street to open lower after Nasdaq's worst week since March 2020
Stocks making the biggest moves in the premarket: Kohl's, Snap, Peloton and more
Earnings playbook: A complete guide to this week's reports, including the first of tech
Frequently asked questionsWhat percentage of Nabriva Therapeutics is owned by insiders or institutions?
Currently 0.45% of Nabriva Therapeutics shares are held by insiders and 14.719% by institutions. How many people work for Nabriva Therapeutics?
Latest data suggests 72 work at Nabriva Therapeutics. When does the fiscal year end for Nabriva Therapeutics?
Nabriva Therapeutics's fiscal year ends in December. Where is Nabriva Therapeutics based?
Nabriva Therapeutics's address is: 25-28 North Wall Quay, Dublin, Ireland, 1 What is Nabriva Therapeutics's ISIN number?
Nabriva Therapeutics's international securities identification number is: IE00BL53QQ85 What is Nabriva Therapeutics's CUSIP number?
Nabriva Therapeutics's Committee on Uniform Securities Identification Procedures number is: 62957M104
More guides on Finder
Today’s top U.S. stocks: Mechel Pao ADRs (MTL ↑8.1%), Sibanye-Stillwater Limited (SBSW ↑7.4%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
How to order free at-home COVID tests today — but note, there’s a wait
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
Today’s top U.S. stocks: Las Vegas Sands (LVS ↑15.3%), Wynn Resorts Limited (WYNN ↑9.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Ask an Expert